目前，多种细胞周期抑制剂正在包括HCC在内的多种实体肿瘤（例如，临床试验NCT02465060）中进行临床试验。尽管前景看好，但内在性和适应性耐药在很大程度上限制了其疗效。大多数研究主要关注基因突变和信号转导通路，例如RB1突变以及细胞周期蛋白D或磷 ...

在这项最新研究中，研究团队进行了体内激酶组 CRISPR 筛选，从中确定了 CDK10 是肿瘤免疫监视的关键抑制因子。 从机制上来说，CDK10 通过磷酸化 DNMT1 和 RAP80 来减少双链 RNA 和 R-loop 的积累，从而减轻由 ...

该公司的生物团队在将创新产品成功推向市场的各个方面拥有150多年的丰富经验，首席医疗和科学官Christine Ginocchio博士是分子诊断学和临床微生物学领域的世界知名专家。她曾是60多项工业和制药临床试验的主要研究者，其中包括21项体外诊断设备研究，获得了美国食品药品管理局 (FDA) 的批准。她的研究将给VedaBio带来技术支撑。

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

Children and adults with rare, deadly genetic diseases have fresh hope for curative therapies, thanks to a new collaboration between the Innovative Genomics Institute (IGI) and Danaher Corporation, a ...

Nine people with a rare genetic condition that causes life-threatening inflammatory reactions appear to have been cured, after taking part in the first trial of a new version of a CRISPR-based gene ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT in 2021 after covering health and science at WIRED. You can reach ...